1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Avicanna Inc.

Avicanna Inc.

AVCN.TO
Avicanna Inc.CA flagToronto Stock Exchange
0.12
CAD
- -
- -
14.47MMarket Cap
Avicanna Inc.
AVCN.TO
(Toronto Stock Exchange)

Recent

price

0.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
0.01
0.05
0.08
0.07
0.2
0.25
0.22
0.22
Revenue per Share
- -
-0.19
-0.45
-1.08
-1.12
-0.41
-0.25
-0.1
-0.04
-0.02
-0.03
Basic EPS, GAAP
- -
-0.19
-0.57
-1.29
-0.53
-0.3
-0.13
-0.02
-0.03
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
0.75
0.74
-0.16
-0.27
-0.27
-0.21
-0.16
-0.15
-0.14
Book Value per Share
- -
0.05
0.79
0.76
0.46
0.16
0.06
0.08
0.08
0.09
0.1
Tangible Book Value per Share
11
14
16
21
29
41
59
85
100
115
115
Basic Weighted Avg Shares
- -
- -
- -
- -
2
3
4
17
25
25
26
Sales/Revenue/Turnover
- -
-9,697.64
-7,159.47
-13,802.86
-1,209.41
-349.15
-257.18
-49.9
-22.16
-10.92
-12.33
Operating Margin (%)
- -
- -
- -
1
1
1
1
1
1
1
1
Depreciation Expense
- -
-3
-7
-22
-33
-17
-15
-9
-4
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-9,750.46
-6,017.63
-13,202.24
-2,093.02
-513.15
-364.02
-52.07
-15.68
-11.16
-12.42
Profit Margin (%)
- -
- -
-1
-5
-6
-5
-4
-4
-2
-1
- -
Working Capital
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
26
30
14
7
3
8
10
11
13
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-119.28
-164.56
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
118
118
126
Market Capitalization
28
25
17

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8
8
8
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
2
3
3
Inventories
5
4
4
Total Current Liabilities
9
9
9
Payables & Accruals
8
9
8
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.86%
17.33%
Free Cash Flow
- -
-27%
-51.28%
Net Income, GAAP
- -
-36.98%
-28.77%
Sales/Revenue/Turnover
- -
99.71%
0.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
6
6
7
25
2025
6
6
6
7
25
2026
7
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.02
-0.01
- -
-0.04
2025
- -
-0.01
-0.01
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Biome Grow Inc. (BIO.CN)
PotNetwork Holdings, Inc. (POTN)
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS)
Dr. Reddy's Laboratories Limited (RDY)
Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262.SZ)
Daewoong pharmaceutical Co.,Ltd (069620.KS)
Business
Avicanna Inc. operates as a commercial-stage biopharmaceutical enterprise, dedicated to the global research, development, and commercialization of advanced cannabinoid-based offerings for medical and pharmaceutical segments. The company cultivates a robust scientific foundation, collaborating with prominent Canadian academic and clinical institutions, driving a pipeline that has yielded over thirty proprietary, evidence-based finished products across four key commercial pillars. Its diverse product portfolio encompasses the RHO Phyto™ medical cannabis formulary, providing a spectrum of oral, sublingual, topical, and transdermal delivery systems featuring various ratios of CBD, CBG, and THC. Avicanna also manages MyMedi.ca, a dedicated medical cannabis care platform offering extensive product selections and pharmacist-led patient support. Furthermore, the company supplies active pharmaceutical ingredients (APIs), including CBD, THC, and CBG, sourced sustainably from its Colombian cultivation operations under the Aureus Santa Marta™ brand, serving international partners. Avicanna maintains an active pharmaceutical pipeline, advancing proprietary cannabinoid-based drug candidates through various clinical stages to address unmet medical needs in areas such as dermatology, chronic pain, and diverse neurological conditions. Recent advancements include preclinical data and patent filings for a novel oral drug delivery platform designed to enhance cannabinoid absorption, alongside issued U.S. patents for topical pain relief compositions and self-emulsifying drug delivery systems. The company has also sponsored a pilot Phase II clinical study investigating oral cannabis extracts for osteoarthritis pain. With a focus on expanding its global footprint, Avicanna has successfully commercialized its products into twenty-three international markets. Recent corporate milestones include achieving its first profitable quarter in Q1 2025 and reporting record revenue of $25.5 million for the full year 2024, reflecting growth in both Canadian and international operations. Strategic collaborations, such as a scientific and medical affairs agreement with Vectura Fertin Pharma, a subsidiary of Philip Morris International, and a partnership with the Nurse Practitioners' Association of Ontario for medical cannabis education, underscore its commitment to scientific validation and market penetration. Established in Toronto, Canada, in 2016, Avicanna continues to emphasize an evidence-based approach in the evolving cannabinoid biopharmaceutical landscape.

Company News

APIChatGPT